Autolus Therapeutics (AUTL) Set to Announce Quarterly Earnings on Tuesday

Autolus Therapeutics (NASDAQ:AUTL) will release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Autolus Therapeutics to post earnings of ($0.21) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Stock Down 7.7 %

Shares of AUTL opened at $3.73 on Friday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $3.99 and a 200 day moving average of $4.01. The company has a market cap of $992.52 million, a PE ratio of -3.22 and a beta of 2.04. Autolus Therapeutics has a 52-week low of $3.06 and a 52-week high of $7.45.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.